Julia von Tresckow

10PUBLICATIONS
37CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Radiation therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Sep 04, 2025
Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn

|Aug 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza

|Jun 10, 2025
Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor.

Maria Dampmann, Bastian von Tresckow, Hans Christian Reinhardt

|Jun 10, 2024
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.

Melina Sophie Kurte, Ann-Cathrine Siefen, Florian Jakobs

|May 02, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.

Nadine Kutsch, Adam Giza, Sandra Robrecht

Pageof 2

Frequent Collaborators

4 joint publications

Moritz Fürstenau

3 joint publications

Michael J Hallek

3 joint publications

Florian Simon

3 joint publications

Sandra Robrecht